🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#KEYNOTEB96 shows success in platinum-resistant recurrent ovarian cancer (PRROC)! ✅ PFS benefit in all comers ✅ OS benefit in PD-L1+ tumors (CPS ≥1) ✅ First ICI regimen to show OS gain in PRROC Treatment arms: 1️⃣ KEYTRUDA (400 mg q6w IV) + paclitaxel ± bevacizumab 2️⃣ Placebo

This is one of the most amazing papers ever. Future Nobel?? NEJM drive.google.com/file/d/1Jfku5j…

4 things clinicians do that patients don’t see: • Answering a call from the ER at 4 am to guide care • Waiting on hold for an hour after insurance denied treatment • Coordinating care with their other doctors after work • Thinking about them in the spaces between visits

What a way to end clinic! United Healthcare just denied prophylactic surgery for a patient with BRCa1 mutation!! This ridiculousness needs to end and shame on United Healthcare!

Here are my top 10 for gynecologic cancers at #ASCO25 Can't wait to see you all there! Debra Richardson, M.D. Shannon Westin, MD, MPH, FASCO BJ Rimel Robert Wenham what are you excited to see?

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

🙌ROSELLA ! Overall survival benefit (👍PFS benefit too) with the addition of relacorilant (glucocorticoid antagonist) to nab-paclitaxel in platinum resistant #ovariancancer 🎉🔥Another big win for our patients!!! #ASCO25 #gyncsm

Wonderful! Congrats

This is a Neurosurgeon at UCLA He has a patient that has brain tumors 🚨 UnitedHealthcare has denied his patient a MRI for lifesaving imaging and THEY’RE DENYING DOING PEER TO PEERS A Peer to Peer is how doctors could appeal the insurance company decision “So UnitedHealthcare

From the June Issue of Annals of Surgical Oncology: Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage #OvarianCancer Adrian Kohut rdcu.be/ereV5 @EdiBonci Syed A. Ahmad

Promising step for cancer and autoimmune disease! No labs. No lymphodepletion. No waiting. In vivo CAR-T is here. 🦠💉🧬This new method avoids the need to make CAR T cells outside the body, which could make the treatment easier to produce, more widely available, and useful for

🔬 ADCs in Platinum-Sensitive Ovarian Cancer (PSOC) – Promising but early days 🧵👇 💥 Four ADCs in play: • 🔗 Sac-TMT: Belotecan payload, TROP2 target • 💣 Dato-DXd: Deruxtecan payload, TROP2 target • 🎯 PICCOLO: DM4 payload, FRα target • 🧬 Raludotug: Deruxtecan payload,

Our new publication in The Green Journal, Uterine Transposition as a novel surgical approach to preserve both ovarian and uterine function during pelvic radiotherapy. Proud to collaborate with an incredible team! lnkd.in/edDwWyYb #UterineTransposition #GynOnc #Fertility

Nivolumab and ipilimumab were effective in treating advanced gynecological clear cell cancers, with a 54% response rate and 58% six-month progression-free survival. ja.ma/44KY8me

Nivo + Ipi combo shows 54% ORR in gynecologic clear cell cancers (CCOC/CCEC) All responses still ongoing. 6-month PFS: 58%. JAMA Oncology OncoAlert jamanetwork.com/journals/jamao…

I’m sharing an actual recent peer-to-peer call that shows what physicians and patients face when trying to get a surgery approved. This call felt as absurd as it sounds. The peer-to-peer call was to advocate for surgery to prevent and treat lymphedema for a patient with breast

Avutometinib and defactinib in low grade ovarian cancer - FDA accelerated approval for KRAS altered tumors and ongoing RAMP 301 will answer efficacy question for KRASwt. This is the first approval in LGS and the first big advance for our patients. Understanding toxicity

Phase 2 RAMP201 (ENGOTov60/GTG-UK/GOG3052)trial leading to FDA accelerated approval avumetinib and defactinib now published Journal of Clinical Oncology Verastem Oncology First approved therapy for low grade serous ovarian cancer. Thanks all. ESGO The GOG Foundation Inc. ESMO - Eur. Oncology

Fascinating paper in Cancer Cell by Charles Swanton => direct functional evidence for cancer cell-intrinsic subclonal immune evasion in 3 different settings in lung cancer: different subclones = different responses to immune pressure

(Breast) Cancer care shouldn’t be a luxury. We lose lives not just to cancer, but to lack of access, high costs, and trials that exclude too many. Innovation must reach every patient, everywhere! nature G Curigliano MD PhD Sherene Loi, MD ESMO - Eur. Oncology ASCO Breast Cancer Now Tatiana Prowell, MD Union for International #CancerControl